NCT04718896View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

March 12, 2025

Study Completion Date

March 12, 2025

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG

bimekizumab

Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.

Trial Locations (11)

46250

Ps0020 50344, Indianapolis

77433

Ps0020 50359, Cypress

Unknown

Ps0020 50354, Calgary

Ps0020 50357, St. John's

Ps0020 40645, Frankfurt

Ps0020 40626, Bialystok

Ps0020 40625, Lodz

Ps0020 40396, Rzeszów

Ps0020 40335, Warsaw

Ps0020 40333, Wroclaw

Ps0020 40334, Wroclaw

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY

NCT04718896 - A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter